| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascorbic Acid | 14 | 2012 | 66 | 2.230 |
Why?
|
| Neoplasms | 17 | 2021 | 1103 | 1.740 |
Why?
|
| Occupational Exposure | 2 | 2024 | 79 | 1.090 |
Why?
|
| Vitamins | 8 | 2017 | 94 | 0.970 |
Why?
|
| Stress, Psychological | 6 | 2014 | 583 | 0.900 |
Why?
|
| Micronutrients | 4 | 2015 | 44 | 0.880 |
Why?
|
| Mutation | 11 | 2016 | 1095 | 0.780 |
Why?
|
| Antioxidants | 7 | 2005 | 416 | 0.740 |
Why?
|
| Etoposide | 1 | 2019 | 22 | 0.700 |
Why?
|
| Charcot-Marie-Tooth Disease | 4 | 2015 | 6 | 0.690 |
Why?
|
| Exosomes | 1 | 2021 | 101 | 0.680 |
Why?
|
| Lipid Peroxidation | 7 | 1998 | 140 | 0.680 |
Why?
|
| Cisplatin | 1 | 2019 | 72 | 0.670 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 58 | 0.670 |
Why?
|
| Enzymes | 3 | 2015 | 32 | 0.660 |
Why?
|
| Humans | 67 | 2024 | 37093 | 0.640 |
Why?
|
| Dietary Supplements | 5 | 2015 | 208 | 0.640 |
Why?
|
| Malnutrition | 3 | 2015 | 44 | 0.620 |
Why?
|
| Breast Neoplasms | 9 | 2013 | 1502 | 0.620 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 110 | 0.620 |
Why?
|
| Students | 5 | 2013 | 519 | 0.610 |
Why?
|
| Adenosine Triphosphatases | 2 | 2016 | 82 | 0.610 |
Why?
|
| Feeding Behavior | 5 | 2015 | 454 | 0.600 |
Why?
|
| Software | 3 | 2019 | 217 | 0.550 |
Why?
|
| Models, Biological | 6 | 2015 | 677 | 0.540 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 33 | 0.490 |
Why?
|
| Cell Cycle Proteins | 2 | 2014 | 229 | 0.470 |
Why?
|
| Stress, Physiological | 1 | 2014 | 150 | 0.440 |
Why?
|
| Energy Metabolism | 2 | 2015 | 168 | 0.410 |
Why?
|
| Diet | 3 | 2014 | 801 | 0.400 |
Why?
|
| Minerals | 3 | 2015 | 47 | 0.390 |
Why?
|
| Genomics | 1 | 2013 | 223 | 0.390 |
Why?
|
| Fish Oils | 4 | 1995 | 12 | 0.380 |
Why?
|
| Dietary Fats | 5 | 1998 | 119 | 0.370 |
Why?
|
| Spastic Paraplegia, Hereditary | 3 | 2016 | 11 | 0.370 |
Why?
|
| Female | 33 | 2022 | 20969 | 0.360 |
Why?
|
| DNA Replication | 3 | 2005 | 152 | 0.350 |
Why?
|
| Industry | 1 | 2009 | 22 | 0.330 |
Why?
|
| Pedigree | 8 | 2015 | 79 | 0.330 |
Why?
|
| Middle Aged | 17 | 2019 | 10129 | 0.330 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 519 | 0.320 |
Why?
|
| Male | 26 | 2021 | 20025 | 0.320 |
Why?
|
| Phenotype | 6 | 2016 | 689 | 0.310 |
Why?
|
| Environmental Exposure | 2 | 2023 | 216 | 0.310 |
Why?
|
| Adult | 19 | 2019 | 11712 | 0.300 |
Why?
|
| Obesity | 5 | 2021 | 1067 | 0.300 |
Why?
|
| Nanostructures | 1 | 2009 | 134 | 0.290 |
Why?
|
| Fatty Acids | 3 | 2004 | 127 | 0.290 |
Why?
|
| Genetic Association Studies | 3 | 2016 | 114 | 0.290 |
Why?
|
| Aged | 12 | 2019 | 6741 | 0.280 |
Why?
|
| Smoking | 1 | 2013 | 940 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2015 | 643 | 0.270 |
Why?
|
| Adipose Tissue | 2 | 2021 | 177 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2019 | 1369 | 0.260 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2231 | 0.260 |
Why?
|
| Blood Glucose | 3 | 2015 | 353 | 0.260 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 2 | 2015 | 2 | 0.260 |
Why?
|
| Young Adult | 10 | 2019 | 4268 | 0.250 |
Why?
|
| Sepsis | 2 | 2019 | 80 | 0.250 |
Why?
|
| Genetic Variation | 3 | 2016 | 387 | 0.250 |
Why?
|
| Research | 1 | 2006 | 163 | 0.240 |
Why?
|
| Erythrocyte Membrane | 1 | 2004 | 20 | 0.240 |
Why?
|
| Anti-Obesity Agents | 1 | 2004 | 10 | 0.240 |
Why?
|
| Models, Theoretical | 1 | 2006 | 217 | 0.240 |
Why?
|
| Membrane Lipids | 1 | 2004 | 33 | 0.240 |
Why?
|
| Triglycerides | 1 | 2004 | 138 | 0.230 |
Why?
|
| Self Medication | 2 | 2013 | 13 | 0.230 |
Why?
|
| Animals | 18 | 2021 | 15081 | 0.230 |
Why?
|
| Nursing Care | 1 | 2022 | 7 | 0.220 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 1995 | 70 | 0.220 |
Why?
|
| Cholesterol | 1 | 2004 | 205 | 0.220 |
Why?
|
| Cell Cycle | 1 | 2004 | 326 | 0.220 |
Why?
|
| Orthomolecular Therapy | 1 | 2002 | 3 | 0.210 |
Why?
|
| Copper Sulfate | 1 | 2002 | 5 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 628 | 0.210 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 213 | 0.200 |
Why?
|
| Puerto Rico | 7 | 2013 | 1378 | 0.200 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 307 | 0.200 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 539 | 0.200 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 11 | 0.190 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 803 | 0.190 |
Why?
|
| Endoribonucleases | 1 | 2021 | 23 | 0.190 |
Why?
|
| United States | 4 | 2023 | 4223 | 0.190 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2000 | 26 | 0.190 |
Why?
|
| Helminth Proteins | 1 | 2021 | 25 | 0.190 |
Why?
|
| Risk Assessment | 1 | 2023 | 753 | 0.180 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 113 | 0.180 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 5 | 0.180 |
Why?
|
| Complementary Therapies | 1 | 2000 | 46 | 0.180 |
Why?
|
| Glycoproteins | 1 | 2021 | 106 | 0.180 |
Why?
|
| Child Nutrition Disorders | 1 | 2000 | 9 | 0.180 |
Why?
|
| Risk Factors | 5 | 2023 | 3562 | 0.170 |
Why?
|
| Universities | 5 | 2013 | 442 | 0.170 |
Why?
|
| Neutropenia | 1 | 2019 | 18 | 0.170 |
Why?
|
| Education, Medical | 1 | 2000 | 104 | 0.170 |
Why?
|
| Eating | 1 | 2021 | 166 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.170 |
Why?
|
| Fever | 1 | 2019 | 57 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 1039 | 0.170 |
Why?
|
| Acute Disease | 1 | 2019 | 147 | 0.170 |
Why?
|
| Socioeconomic Factors | 5 | 2013 | 1067 | 0.170 |
Why?
|
| Nutritional Status | 1 | 2000 | 116 | 0.170 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 202 | 0.170 |
Why?
|
| Motor Neuron Disease | 2 | 2015 | 4 | 0.160 |
Why?
|
| Coenzymes | 2 | 2015 | 13 | 0.160 |
Why?
|
| Survival Rate | 1 | 2019 | 311 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2016 | 517 | 0.160 |
Why?
|
| Computational Biology | 3 | 2019 | 293 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2019 | 1378 | 0.160 |
Why?
|
| Neural Tube Defects | 1 | 1997 | 3 | 0.160 |
Why?
|
| Income | 3 | 2013 | 140 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 1997 | 6 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2019 | 2026 | 0.160 |
Why?
|
| Alzheimer Disease | 2 | 2016 | 905 | 0.150 |
Why?
|
| Prognosis | 3 | 2005 | 739 | 0.150 |
Why?
|
| Folic Acid | 1 | 1997 | 46 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 182 | 0.150 |
Why?
|
| Macrophages | 2 | 2021 | 439 | 0.150 |
Why?
|
| Schistosomiasis mansoni | 1 | 2017 | 8 | 0.150 |
Why?
|
| Vitamin A Deficiency | 1 | 2017 | 13 | 0.150 |
Why?
|
| Drinking Behavior | 2 | 2015 | 16 | 0.150 |
Why?
|
| Granuloma | 1 | 2017 | 26 | 0.150 |
Why?
|
| Food | 2 | 2015 | 100 | 0.150 |
Why?
|
| Pregnancy | 2 | 2019 | 1549 | 0.140 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2016 | 7 | 0.140 |
Why?
|
| Receptors, sigma | 1 | 2016 | 15 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 974 | 0.140 |
Why?
|
| Cell Membrane | 2 | 2012 | 381 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 2379 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 276 | 0.140 |
Why?
|
| Pilot Projects | 4 | 2015 | 661 | 0.140 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 16 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 126 | 0.140 |
Why?
|
| Motor Neurons | 2 | 2015 | 83 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2016 | 83 | 0.140 |
Why?
|
| Adolescent | 5 | 2019 | 5363 | 0.140 |
Why?
|
| Adaptation, Psychological | 3 | 2013 | 385 | 0.130 |
Why?
|
| Thiazoles | 1 | 2016 | 74 | 0.130 |
Why?
|
| Phosphate Transport Proteins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2015 | 2 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2015 | 18 | 0.130 |
Why?
|
| Mice | 10 | 2021 | 5913 | 0.130 |
Why?
|
| Lipolysis | 1 | 1995 | 18 | 0.130 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 35 | 0.130 |
Why?
|
| Glycine-tRNA Ligase | 1 | 2014 | 2 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1996 | 172 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 190 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2015 | 93 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2015 | 59 | 0.120 |
Why?
|
| Models, Chemical | 1 | 2016 | 207 | 0.120 |
Why?
|
| Adipocytes | 1 | 1995 | 58 | 0.120 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 107 | 0.120 |
Why?
|
| Cell Death | 3 | 2006 | 267 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 2 | 2013 | 174 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 30 | 0.120 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1998 | 9 | 0.120 |
Why?
|
| Liver | 1 | 2017 | 479 | 0.120 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2013 | 1 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 71 | 0.120 |
Why?
|
| Presenilin-1 | 1 | 2014 | 27 | 0.120 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 8 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 1996 | 357 | 0.120 |
Why?
|
| Genome, Human | 1 | 2014 | 135 | 0.110 |
Why?
|
| Computer Security | 1 | 2013 | 7 | 0.110 |
Why?
|
| Lysosomes | 1 | 2014 | 91 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 215 | 0.110 |
Why?
|
| Caffeine | 1 | 2013 | 28 | 0.110 |
Why?
|
| beta-Glucosidase | 1 | 2013 | 6 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 251 | 0.110 |
Why?
|
| Injections, Intravenous | 4 | 2011 | 62 | 0.110 |
Why?
|
| Benzamides | 1 | 2013 | 78 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 86 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2013 | 62 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2006 | 502 | 0.110 |
Why?
|
| Beverages | 1 | 2013 | 68 | 0.110 |
Why?
|
| Fatigue | 1 | 2013 | 83 | 0.110 |
Why?
|
| Dementia | 1 | 2014 | 131 | 0.110 |
Why?
|
| Fermentation | 1 | 2012 | 26 | 0.110 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 47 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2016 | 1492 | 0.100 |
Why?
|
| Glycolysis | 1 | 2012 | 68 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2014 | 272 | 0.100 |
Why?
|
| Gene Expression | 3 | 2016 | 674 | 0.100 |
Why?
|
| Diabetic Neuropathies | 1 | 2011 | 11 | 0.100 |
Why?
|
| Cell Division | 3 | 2002 | 307 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 767 | 0.100 |
Why?
|
| Internet | 1 | 2013 | 211 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 1991 | 30 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 364 | 0.100 |
Why?
|
| Oxygen | 1 | 2012 | 207 | 0.100 |
Why?
|
| Rats | 3 | 2014 | 3483 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 2721 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 47 | 0.100 |
Why?
|
| Disease Progression | 3 | 2014 | 601 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 148 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 418 | 0.090 |
Why?
|
| Vitamin E | 1 | 1990 | 61 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2006 | 1198 | 0.090 |
Why?
|
| Kinetics | 2 | 2014 | 708 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 935 | 0.090 |
Why?
|
| Receptors, Cell Surface | 3 | 2017 | 144 | 0.090 |
Why?
|
| Weight Loss | 2 | 2015 | 131 | 0.090 |
Why?
|
| Schistosoma mansoni | 2 | 2021 | 18 | 0.090 |
Why?
|
| Inorganic Chemicals | 1 | 2009 | 2 | 0.090 |
Why?
|
| Greenhouse Effect | 1 | 2009 | 5 | 0.090 |
Why?
|
| Nanotubes | 1 | 2009 | 18 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 204 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2012 | 587 | 0.080 |
Why?
|
| Child | 5 | 2016 | 3131 | 0.080 |
Why?
|
| Mitochondria | 1 | 2012 | 487 | 0.080 |
Why?
|
| Carbon | 1 | 2009 | 105 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2009 | 153 | 0.080 |
Why?
|
| Exercise | 1 | 2013 | 613 | 0.070 |
Why?
|
| Mice, Nude | 3 | 1993 | 337 | 0.070 |
Why?
|
| Time Factors | 1 | 2010 | 1742 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2016 | 1418 | 0.070 |
Why?
|
| Syndrome | 2 | 2016 | 74 | 0.070 |
Why?
|
| Premenopause | 2 | 2003 | 104 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 41 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 128 | 0.060 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2005 | 23 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2005 | 145 | 0.060 |
Why?
|
| Nutritional Requirements | 2 | 2015 | 36 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 26 | 0.060 |
Why?
|
| Palliative Care | 1 | 2005 | 49 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 53 | 0.060 |
Why?
|
| Herbal Medicine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2009 | 318 | 0.060 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2003 | 1 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 252 | 0.060 |
Why?
|
| Anthropometry | 1 | 2004 | 97 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 33 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 108 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2004 | 81 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2004 | 286 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 306 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 219 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2005 | 222 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 275 | 0.050 |
Why?
|
| Zebrafish | 2 | 2015 | 128 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 128 | 0.050 |
Why?
|
| Oxidation-Reduction | 2 | 1995 | 431 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 474 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 1993 | 122 | 0.050 |
Why?
|
| Genotype | 2 | 2016 | 730 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 893 | 0.050 |
Why?
|
| Pain | 1 | 2005 | 251 | 0.050 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 160 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1180 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 1046 | 0.050 |
Why?
|
| Thermogenesis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Holistic Health | 1 | 2000 | 13 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 42 | 0.050 |
Why?
|
| Pseudobulbar Palsy | 1 | 2000 | 1 | 0.050 |
Why?
|
| Pica | 1 | 2000 | 2 | 0.050 |
Why?
|
| Starvation | 1 | 2000 | 12 | 0.050 |
Why?
|
| Cerebral Palsy | 1 | 2000 | 12 | 0.050 |
Why?
|
| Locomotion | 1 | 2021 | 97 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2000 | 31 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 515 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 93 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1997 | 5 | 0.040 |
Why?
|
| Cebus | 1 | 1997 | 4 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 935 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 2017 | 6 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 14 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 25 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 29 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2017 | 34 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 36 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2017 | 72 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1996 | 24 | 0.040 |
Why?
|
| Tretinoin | 1 | 2017 | 50 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1518 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2016 | 26 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 268 | 0.030 |
Why?
|
| Hungary | 1 | 2016 | 9 | 0.030 |
Why?
|
| HIV | 1 | 1996 | 98 | 0.030 |
Why?
|
| Free Radicals | 1 | 1996 | 74 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 35 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 61 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 83 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 100 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 1609 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1996 | 65 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 60 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 399 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 195 | 0.030 |
Why?
|
| COS Cells | 1 | 2015 | 69 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1995 | 34 | 0.030 |
Why?
|
| Brain | 2 | 2013 | 1346 | 0.030 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2016 | 83 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2015 | 51 | 0.030 |
Why?
|
| Hela Cells | 1 | 2016 | 366 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 99 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2015 | 59 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2015 | 40 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 33 | 0.030 |
Why?
|
| Aminoacylation | 1 | 2014 | 1 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 146 | 0.030 |
Why?
|
| Yeasts | 1 | 2014 | 19 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 211 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 218 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 89 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 409 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 43 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 215 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2015 | 118 | 0.030 |
Why?
|
| Magnesium | 1 | 2015 | 97 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 119 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 24 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 435 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 35 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2016 | 492 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 75 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 77 | 0.030 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2014 | 4 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 243 | 0.030 |
Why?
|
| Exons | 1 | 2014 | 88 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 93 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 40 | 0.030 |
Why?
|
| Carnitine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Sarcoma | 1 | 1994 | 10 | 0.030 |
Why?
|
| Sural Nerve | 1 | 2013 | 4 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 90 | 0.030 |
Why?
|
| Body Composition | 1 | 1995 | 162 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2013 | 30 | 0.030 |
Why?
|
| Thiobarbiturates | 1 | 1993 | 4 | 0.030 |
Why?
|
| Riboflavin | 1 | 2013 | 24 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 61 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 302 | 0.030 |
Why?
|
| Cacao | 1 | 2013 | 10 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2013 | 29 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 235 | 0.030 |
Why?
|
| Carbonated Beverages | 1 | 2013 | 21 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2014 | 172 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 339 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 26 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 217 | 0.030 |
Why?
|
| Coffee | 1 | 2013 | 20 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 2013 | 7 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2013 | 30 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1995 | 230 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 50 | 0.030 |
Why?
|
| Tea | 1 | 2013 | 45 | 0.030 |
Why?
|
| Proteins | 1 | 2016 | 369 | 0.030 |
Why?
|
| Corn Oil | 1 | 1992 | 1 | 0.030 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1992 | 2 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 1992 | 15 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 282 | 0.030 |
Why?
|
| Hydroquinones | 1 | 1992 | 8 | 0.030 |
Why?
|
| Food Preservation | 1 | 1992 | 7 | 0.030 |
Why?
|
| Carcinoma | 1 | 1994 | 96 | 0.030 |
Why?
|
| Peroxides | 1 | 1992 | 20 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 864 | 0.030 |
Why?
|
| Adenoma | 1 | 1994 | 89 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 623 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 173 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 352 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 37 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 972 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 333 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 610 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 241 | 0.030 |
Why?
|
| Research Design | 1 | 2013 | 313 | 0.020 |
Why?
|
| Family | 1 | 2013 | 173 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 362 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1991 | 90 | 0.020 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 2011 | 2 | 0.020 |
Why?
|
| Endothelium | 1 | 2011 | 31 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 1991 | 51 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1992 | 661 | 0.020 |
Why?
|
| Immunity | 1 | 2011 | 53 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 65 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 191 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 571 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1990 | 26 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 481 | 0.020 |
Why?
|
| Weight Gain | 1 | 1991 | 136 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 1990 | 30 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1990 | 62 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 2 | 1998 | 111 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 88 | 0.020 |
Why?
|
| Postmenopause | 2 | 1998 | 128 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 224 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 54 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 88 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 1175 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 143 | 0.020 |
Why?
|
| Terminal Care | 1 | 2005 | 45 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 1998 | 1130 | 0.020 |
Why?
|
| Age Factors | 2 | 1998 | 1033 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2003 | 36 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2003 | 22 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2003 | 43 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 64 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2003 | 78 | 0.010 |
Why?
|
| HIV Infections | 1 | 1996 | 2303 | 0.010 |
Why?
|
| Menarche | 1 | 1998 | 13 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1998 | 27 | 0.010 |
Why?
|
| Energy Intake | 1 | 1998 | 170 | 0.010 |
Why?
|